UNITED STATES SECURITIES AND EXCHANGE COMMISSION Cardio Diagnostics Holdings, Inc. Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-41097 (Exact name of registrant as specified in its charter) (State or other jur ...

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will be presenting new data at the American Heart Association (AHA) Scientific Sessions. ...

Oct 28, 2025 8:35 AM Eastern Daylight Time Cardio Diagnostics Holdings, Inc. and YMCA of East Tennessee Partner to Bring Heart Health Education and Advanced Testing to East Tennessee Community Share A customized program for YMCA of East Tennessee members will include educational series "Wisdom Wednesdays,†and access to Cardio Diagnostics' AI-powered cardiovascular testing at discounted rates from home or during the Heart Health Fair KNOXVILLE, Tenn. & CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, I ...

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. today announced the Company has partnered with 15 new provider organizations across the United States. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-41097 311 West Superior Street, Suite 444 Chicago, Illinois 60654 (Address of principal executive offices) (Zip Code) C ...

Part I — Financial Information [Financial Statements (unaudited)](index=5&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) The company's unaudited Q1 2025 financial statements show a net loss of **$1.64 million**, a significant reduction from **$4.16 million** in Q1 2024, with cash and assets increasing after a reverse stock split Condensed Consolidated Balance Sheets (unaudited) | | March 31, 2025 ($) | December 31, 2024 ($) | | :--- | :--- | :--- | | **Total current assets** | **$10.54 million** | **$8.79 million** | | **Total assets** | **$12.28 million** | **$10.62 million** | | **Total current liabilities** | **$0.54 million** | **$0.63 million** | | **Total liabilities** | **$0.90 million** | **$1.06 million** | | **Total stockholders' equity** | **$11.38 million** | **$9.56 million** | Condensed Consolidated Statements of Operations (unaudited) | | Three Months Ended March 31, 2025 ($) | Three Months Ended March 31, 2024 ($) | | :--- | :--- | :--- | | **Revenue** | **$940** | **$15.93 thousand** | | **Total operating expenses** | **$1.63 million** | **$4.17 million** | | **Loss from operations** | **($1.63 million)** | **($4.16 million)** | | **Net loss** | **($1.64 million)** | **($4.16 million)** | | **Net loss per common share** | **($0.97)** | **($5.93)** | Condensed Consolidated Statements of Cash Flows (unaudited) | | Three Months Ended March 31, 2025 ($) | Three Months Ended March 31, 2024 ($) | | :--- | :--- | :--- | | **Net cash used in operating activities** | **($1.40 million)** | **($1.23 million)** | | **Net cash used in investing activities** | **($47.42 thousand)** | **($69.94 thousand)** | | **Net cash provided by financing activities** | **$3.31 million** | **$1.58 million** | | **Net increase in cash** | **$1.86 million** | **$279.62 thousand** | | **Cash - End of period** | **$9.69 million** | **$1.56 million** | - On May 12, 2025, the company executed a 1-for-30 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement. All share and per-share amounts in the financial statements have been retroactively adjusted[35](index=35&type=chunk)[37](index=37&type=chunk)[111](index=111&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=27&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the significant reduction in Q1 2025 net loss to **$1.64 million**, driven by lower stock-based compensation, and highlights the company's focus on commercializing AI-driven cardiovascular tests and securing **$14.68 million** in ATM financing - The company's primary business is developing and commercializing AI-driven, epigenetics-based clinical tests for cardiovascular diseases like coronary heart disease (CHD), stroke, and heart failure[118](index=118&type=chunk)[119](index=119&type=chunk) - The significant decrease in net loss for Q1 2025 compared to Q1 2024 was primarily driven by a **$2.58 million** reduction in General and Administrative expenses, largely due to lower stock compensation expense (**$30.61 thousand** in Q1 2025 vs. **$2.52 million** in Q1 2024)[131](index=131&type=chunk)[136](index=136&type=chunk) - As of May 15, 2025, the company has raised **$14.68 million** in net proceeds from its At-the-Market (ATM) sales agreement, which serves as a primary source of liquidity[126](index=126&type=chunk)[144](index=144&type=chunk) - Management anticipates that existing funds will be sufficient to fund activities for the next 12 months, but acknowledges the need to raise additional capital through equity or debt to support operations beyond that period[151](index=151&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=38&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a "smaller reporting company," the company is not required to provide quantitative and qualitative disclosures about market risk - Pursuant to Item 305(e) of Regulation S-K, the Company is not required to provide market risk disclosures as it qualifies as a "smaller reporting company"[176](index=176&type=chunk) [Controls and Procedures](index=38&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were ineffective as of March 31, 2025, due to a material weakness in internal control over financial reporting, with remediation plans in progress - Management identified a material weakness in internal control over financial reporting: inadequate segregation of duties within the financial reporting process due to limited staff resources[179](index=179&type=chunk) - Remediation plans are in progress and include developing a formalized approval matrix for significant financial transactions and exploring the automation of key accounting processes[180](index=180&type=chunk)[183](index=183&type=chunk) Part II — Other Information [Legal Proceedings](index=39&type=section&id=Item%201.%20Legal%20Proceedings) As of March 31, 2025, the company is not a party to any litigation deemed material to its ongoing operations - The Company reports that it is not a party to any material litigation as of the period ended March 31, 2025[185](index=185&type=chunk) [Risk Factors](index=39&type=section&id=Item%201A.%20Risk%20Factors) No material changes to the risk factors previously disclosed in the company's 2024 Annual Report on Form 10-K have been reported - No material changes to the risk factors from the company's 2024 Annual Report on Form 10-K have been reported[186](index=186&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=39&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities or use of proceeds during the quarter - None reported for the period[187](index=187&type=chunk) [Other Information](index=39&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted, modified, or terminated a Rule 10b-5 trading arrangement during the fiscal quarter ended March 31, 2025 - No directors or officers adopted, modified, or terminated a Rule 10b-5 trading arrangement during the quarter[190](index=190&type=chunk) [Exhibits](index=39&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed as part of the Quarterly Report on Form 10-Q, including required officer certifications - The report includes a list of filed exhibits, such as the Agreement and Plan of Merger, Certificate of Incorporation, and various officer certifications required by the Sarbanes-Oxley Act[191](index=191&type=chunk)[192](index=192&type=chunk)[193](index=193&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41097 Redeemable warrants, each warrant exercisable for one share of common stock CDIOW The Nasdaq Stock Market LLC CARDIO DIAGNOSTICS HOLD ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-41097 Cardio Diagnostics Holdings, Inc. (Exact name of registrant as specified in its charter) | --- | --- | --- | |- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-41097 Cardio Diagnostics Holdings, Inc. (Exact name of registrant as specified in its charter) | --- | --- | --- | |------ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-41097 Cardio Diagnostics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 87-0925574 (State ...